Relay Therapeutics (RLAY) News Today $3.69 +0.12 (+3.36%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.70 +0.02 (+0.41%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Relay Therapeutics Up Today?Toggle Visibility of Why Is Relay Therapeutics Up Today?Investors in Relay Therapeutics, Inc. (NASDAQ:RLAY) saw shares respond as HC Wainwright updated multiple earnings forecasts, cut its price target and the company lined up investor conference appearances. Positive Sentiment: Relay announced that management will participate in two investor conferences in September, offering more insight into its precision‐medicine pipeline. Relay Therapeutics to Participate in Investor Conferences Positive Sentiment: HC Wainwright raised several 2025 earnings estimates, lifting Q3 2025 EPS to ($0.38) from ($0.48), Q4 2025 EPS to ($0.38) from ($0.49) and boosting full-year 2025 EPS to ($1.62) from ($1.92), signaling an improving operational outlook. Free Report Neutral Sentiment: Equities analysts at HC Wainwright published detailed EPS forecasts for Q1–Q4 2026 and FY 2026, maintaining a “Buy” rating and a $14.00 target, with FY 2026 EPS expected around (-$2.55). Brokers Offer Predictions for RLAY FY2026 Earnings Negative Sentiment: HC Wainwright cut its 12-month price target on RLAY to $14.00 from $16.00, though it kept its “Buy” rating in place. Price Target Cut to $14.00 by HC Wainwright Negative Sentiment: HC Wainwright issued a pessimistic forecast for Relay’s stock price, dampening near-term sentiment. Pessimistic Forecast for RLAY Stock Price Posted 31m agoAI Generated. May Contain Errors. RLAY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Brokers Offer Predictions for RLAY FY2026 Earnings2 hours ago | marketbeat.comWhat is HC Wainwright's Forecast for RLAY FY2026 Earnings?August 29 at 2:56 AM | americanbankingnews.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberAugust 28 at 4:05 PM | globenewswire.comRelay Therapeutics (NASDAQ:RLAY) Price Target Cut to $14.00 by Analysts at HC WainwrightAugust 28 at 8:20 AM | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock PriceAugust 28 at 2:13 AM | americanbankingnews.comRelay Therapeutics price target lowered to $14 from $16 at H.C. WainwrightAugust 27 at 2:56 AM | msn.comCandriam S.C.A. Sells 1,149,063 Shares of Relay Therapeutics, Inc. $RLAYAugust 26 at 4:49 AM | marketbeat.comLeerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PTAugust 26 at 3:53 AM | msn.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 26 at 2:26 AM | marketbeat.comRaymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost CutsAugust 18, 2025 | msn.comRelay Therapeutics (RLAY) Gets a Buy from Bank of America SecuritiesAugust 9, 2025 | theglobeandmail.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst DowngradeAugust 9, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Price Target Lowered to $19.00 at Raymond James FinancialAugust 9, 2025 | marketbeat.comRelay (RLAY) Q2 Loss Narrows 41%August 7, 2025 | fool.comRelay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate UpdatesAugust 7, 2025 | globenewswire.comRelay Therapeutics Q2 2025 Earnings PreviewAugust 7, 2025 | seekingalpha.comPreview: Relay Therapeutics's EarningsAugust 7, 2025 | benzinga.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 8.2% - Here's What HappenedAugust 5, 2025 | marketbeat.comBarclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PTAugust 5, 2025 | msn.comRelay Therapeutics: What's Next For H2 2025?August 2, 2025 | seekingalpha.comBarclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)August 1, 2025 | msn.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 4,069 Shares of StockJuly 31, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 15,724 SharesJuly 31, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 18,276 Shares of StockJuly 31, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 18,380 SharesJuly 31, 2025 | marketbeat.comDonald A. Bergstrom Sells 26,701 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJuly 31, 2025 | marketbeat.comRelay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025July 31, 2025 | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $15,218.06 in StockJuly 31, 2025 | insidertrades.comRelay Therapeutics (RLAY) to Release Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comRelay Therapeutics has positive read from Celcuity data, says BarclaysJuly 30, 2025 | finance.yahoo.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 30, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sees Large Volume Increase - Still a Buy?July 25, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 5.6% - Should You Buy?July 16, 2025 | marketbeat.comPrivate Capital Advisors Inc. Acquires Shares of 100,000 Relay Therapeutics, Inc. (NASDAQ:RLAY)July 14, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 61,379 SharesJuly 11, 2025 | insidertrades.comSanjiv Patel Sells 61,379 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJuly 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (RLAY) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comBofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PTJune 24, 2025 | insidermonkey.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9% - Time to Sell?June 20, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.7% - Here's What HappenedJune 18, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Here's What HappenedJune 13, 2025 | marketbeat.comRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of DirectorsJune 11, 2025 | globenewswire.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher - What's Next?June 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Growth in Short InterestJune 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DEJune 4, 2025 | marketbeat.comSquarepoint Ops LLC Increases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comNuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comJane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comRelay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast CancerJune 2, 2025 | msn.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.931.03▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼175▲RLAY Articles Average Week Get the Latest News and Ratings for RLAY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Relay Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies KNSA News OGN News TARS News CNTA News DNLI News AGIO News IDYA News IBRX News HRMY News RXRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access